Login Register Cart 0
Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Clinical Trial

Predictors of Cardiovascular Affection in Patients with Active Rheumatoid Arthritis: Secondary Analysis of a Randomized Controlled Trial

Author(s): Eman M. Ibrahem*, Salwa S. El-gendi, Amal A. Mahmoud, Sherif M. Abdel-Aal, Fatma H. El Nouby and Hanan Sharaf El-Deen Mohammed

Volume 17, Issue 2, 2021

Published on: 13 November, 2020

Page: [258 - 266] Pages: 9

DOI: 10.2174/1573397116666201113090145

Price: $65

Abstract

Objective: This is a secondary analysis of a randomized controlled trial that aimed to assess subclinical atherosclerosis in patients with rheumatoid arthritis (RA) by measuring carotid artery intima-media thickness (CIMT) and correlating it with disease activity and inflammatory markers (including levels of matrix metalloproteinase-3(MMP-3) and matrix metalloproteinase-9 (MMP-9)) and to detect the effectiveness of agents that inhibit matrix metalloproteinases (MMPs) as doxycycline in RA therapy.

Methods: One hundred and sixty RA patients were assigned in a randomized clinical trial (clinicaltrial. gov NCT03194204). Disease activity score 28(DAS28), laboratory markers, including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), MMP-3, and MMP-9 were evaluated and mean CIMT was measured. Subjects were allocated randomly into one of two treatment arms, either methotrexate (MTX) alone or MTX with doxycycline 200mg per day orally. Follow up ESR, CRP, DAS28, MMP-3, and MMP-9 levels were re-evaluated after 3 months.

Results: There were positive significant correlations between CIMT and disease duration (r = 0.461, p = 0.001), age (r=0.459, p= 0.001), DAS28 score (r= 0.547, p = 0.001), ESR (r =0.413, p = 0.001), CRP (r = 0.281, p = 0.001), MMP-3 (r = 0.476, p = 0.001), and MMP-9 (r = 0.593, p =0.001). Patients treated with MTX and doxycycline showed lower levels of DAS28, ESR, CRP, MMP-3, and MMP-9 and this was statistically significant.

Conclusion: CIMT seems to be the ultimate method to screen for subclinical atherosclerosis in RA patients. MMP-3 and 9 play a key role in both RA synovitis and cardiovascular changes, making them important therapeutic targets, especially with safe and cost-effective agents like doxycycline. This clinical trial was carried out in Assiut University Hospital (AUH), Assiut, Egypt (Clinical Trial Registration No. clinicaltrial.gov NCT03194204).

Keywords: Rheumatoid arthritis, matrix metalloproteinases, atherosclerosis, randomized clinical trial, combination therapy, CIMT.

« Previous Next »
Graphical Abstract

[1]
Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003; 423(6937): 356-61.
[http://dx.doi.org/10.1038/nature01661] [PMID: 12748655]
[2]
McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365(23): 2205-19.
[http://dx.doi.org/10.1056/NEJMra1004965] [PMID: 22150039]
[3]
Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci 2006; 11(1): 529-43.
[http://dx.doi.org/10.2741/1817] [PMID: 16146751]
[4]
Mittal B, Mishra A, Srivastava A, Kumar S, Garg N. Matrix metalloproteinases in coronary artery disease. Adv Clin Chem 2014; 64: 1-72.
[http://dx.doi.org/10.1016/B978-0-12-800263-6.00001-X] [PMID: 24938016]
[5]
Ma JD, Zhou JJ, Zheng DH, et al. Serum matrix metalloproteinase-3 as a noninvasive biomarker of histological synovitis for diagnosis of rheumatoid arthritis Mediators Inflamm 2014.
[http://dx.doi.org/10.1155/2014/179284]
[6]
Steenport M, Khan KM, Du B, Barnhard SE, Dannenberg AJ, Falcone DJ. Matrix metalloproteinase (MMP)-1 and MMP-3 induce macrophage MMP-9: evidence for the role of TNF-alpha and cyclooxygenase-2. J Immunol 2009; 183(12): 8119-27.
[http://dx.doi.org/10.4049/jimmunol.0901925] [PMID: 19923455]
[7]
Manole C, Elena R, Mihaela CI, Isabela SJS. Measurement of serum matrix metalloproteinase 9 in patients with early rheumatoid arthritis Med Con 2013; 8: 9-11.
[8]
Biskup M, Biskup W, Majdan M, Targońska-Stępniak B. Cardiovascular system changes in rheumatoid arthritis patients with continued low disease activity. Rheumatol Int 2018; 38(7): 1207-15.
[http://dx.doi.org/10.1007/s00296-018-4053-x] [PMID: 29774373]
[9]
Dalbeni A, Giollo A, Tagetti A, et al. Traditional cardiovascular risk factors or inflammation: Which factors accelerate atherosclerosis in arthritis patients? Int J Cardiol 2017; 236: 488-92.
[http://dx.doi.org/10.1016/j.ijcard.2017.01.072]
[10]
Pasceri V, Yeh ET. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 1999; 100(21): 2124-6.
[http://dx.doi.org/10.1161/01.CIR.100.21.2124]
[11]
Olson FJ, Schmidt C, Gummesson A, et al. Circulating matrix metalloproteinase 9 levels in relation to sampling methods, femoral and carotid atherosclerosis. J Intern Med 2008; 263(6): 626-35.
[http://dx.doi.org/10.1111/j.1365-2796.2008.01927.x] [PMID: 18341531]
[12]
Rodríguez JA, Orbe J, Páramo JA. Metalloproteases, vascular remodeling and atherothrombotic syndromes. Rev Esp Cardiol 2007; 60(9): 959-67.
[http://dx.doi.org/10.1157/13109649] [PMID: 17915152]
[13]
Nakashima Y, Chen YX, Kinukawa N, Sueishi K. Distributions of diffuse intimal thickening in human arteries: preferential expression in atherosclerosis-prone arteries from an early age. Virchows Arch 2002; 441(3): 279-88.
[http://dx.doi.org/10.1007/s00428-002-0605-1] [PMID: 12242525]
[14]
Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90(3): 251-62.
[http://dx.doi.org/10.1161/res.90.3.251] [PMID: 11861412]
[15]
Jones CB, Sane DC, Herrington DMJCr. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome Cardiovasc Res 2003; 59(4): 812-23.
[http://dx.doi.org/10.1016/S0008-6363(03)00516-9]
[16]
Higashikata T, Yamagishi M, Higashi T, Nagata I, Iihara K, Miyamoto S. Altered expression balance of matrix metalloproteinases and their inhibitors in human carotid plaque disruption: results of quantitative tissue analysis using real-time RT-PCR method. Atherosclerosis 2006; 185(1): 165-72.
[http://dx.doi.org/10.1016/j.atherosclerosis.2005.05.039]
[17]
Sluijter JP, Pulskens WP, Schoneveld AH, Velema E, Strijder CF, Moll F. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke 2006; 37(1): 235-9.
[http://dx.doi.org/10.1161/01.STR.0000196986.50059.e0]
[18]
Dorent R, Beaudeux J. Circulating levels of matrix metalloproteinases in heart transplant recipients. Transplant Proc 2000; 32(8): 2750-1.
[19]
Ludwig M, von Petzinger-Kruthoff A, von Buquoy M, Stumpe KO. Intima media thickness of the carotid arteries: early pointer to arteriosclerosis and therapeutic endpoint. Ultraschall Med 2003; 24(3): 162-74.
[http://dx.doi.org/10.1055/s-2003-40058] [PMID: 12817310]
[20]
Greenwald RA, Moak SA, Ramamurthy NS, Golub LM. Tetracyclines suppress matrix metalloproteinase activity in adjuvant arthritis and in combination with flurbiprofen, ameliorate bone damage. J Rheumatol 1992; 19(6): 927-38.
[PMID: 1404131]
[21]
Smith GN Jr, Brandt KD, Hasty KAJA. Activation of recombinant human neutrophil procollagenase in the presence of doxycycline results in fragmentation of the enzyme and loss of enzyme activity Arthritis Rheum 1996; 39(2): 235-44.
[http://dx.doi.org/10.1002/art.1780390209]
[22]
Stone M, Fortin PR, Pacheco-Tena C, Inman RDJTJ. Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity. J Rheumatol 2003; 30(10): 2112-22.
[23]
O’Dell JR, Elliott JR, Mallek JA, et al. Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone. Arthritis Rheum 2006; 54(2): 621-7.
[http://dx.doi.org/10.1002/art.21620] [PMID: 16447240]
[24]
Aletaha D, T, Neogi AJ, Silman J, Funovits DT, Felson CO, Bingham III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62(9): 2569-81.
[25]
Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012; 64(5): 625-39.
[26]
Larsen AJT. How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in long-term studies. J Rheumatol 1995; 22(10): 1974-5.
[27]
Health NIo. National Cancer Institute. Common Terminology Criteria for Adverse Events 2019; 5(November): 2017.
[28]
Del Rincón I, Williams K, Stern MP, Freeman GL, Escalante AJA, Rheumatology ROJotACo. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44(12): 2737-45.
[http://dx.doi.org/10.1002/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-#]
[29]
Cao JJ, Arnold AM, Manolio TA, et al. Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study. Circulation 2007; 116(1): 32-8.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.106.645606] [PMID: 17576871]
[30]
Centurión OAJEC. Carotid intima-media thickness in rheumatoid arthritis: how helpful it is to know the presence of subclinical atherosclerosis. EC Cardiology 2019; 6: 505-8.
[31]
Singh H, Goyal M, Sen J, Kumar H, Handa R, Garg SJJIACM. Correlation of intima-media thickness (as a marker of atherosclerosis) with activity and duration of rheumatoid arthritis using carotid ultrasound. J Indian Acad Clin Med 2011; 12(1): 15-20.
[32]
Saigal R, Mathur V, Goyal LJIJAM. Carotid intima media thickness as a marker of subclinical atherosclerosis in rheumatoid arthritis: a case control study. IntJAdvMed 2016; 3: 942-6.
[http://dx.doi.org/10.18203/2349-3933.ijam20163728]
[33]
Goodson NJ, Symmons DP, Scott DG, Bunn D, Lunt M, Silman AJJA, et al. Baseline levels of Creactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care–based inception cohort. Arthritis Rheum 2005; 52(8): 2293-9.
[http://dx.doi.org/10.1002/art.21204]
[34]
Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005; 52(3): 722-32.
[http://dx.doi.org/10.1002/art.20878] [PMID: 15751097]
[35]
Everett BM, Pradhan AD, Solomon DH, Paynter N, Macfadyen J, Zaharris E, et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis Am Heart J 2013; 166(2): 199-207.
[http://dx.doi.org/10.1016/j.ahj.2013.03.018]
[36]
Aji G, Manuaba IARW, Ongkowijaya JA, Setiyohadi B, Sumariyono SJIJoR. Correlation of matrix metalloproteinase-9 level, erythrocyte sedimentation rate, rheumatoid factor, and the duration of illness with radiological findings in rheumatoid arthritis patients. Indones J Rheumatol 2010; 3: 21-3.
[37]
Sun S, Bay-Jensen A-C, Karsdal MA, Siebuhr AS, Zheng Q, Maksymowych WP, et al. The active form of MMP-3 is a marker of synovial inflammation and cartilage turnover in inflammatory joint diseases. BMC Musculoskeletal Disorders 2014; 15(1): 93.
[http://dx.doi.org/10.1186/1471-2474-15-93]
[38]
Keyszer G, Lambiri I, Nagel R, et al. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J Rheumatol 1999; 26(2): 251-8.
[PMID: 9972954]
[39]
Mamehara A, Sugimoto T, Sugiyama D, Morinobu S, Tsuji G, Kawano S. Serum matrix metalloproteinase-3 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological disease modifying anti-rheumatic drugs Kobe J Med Sci 2010; 56(3): 98-107.
[40]
Ribbens C, Andre B, Jaspar JM, et al. Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis. J Rheumatol 2000; 27(4): 888-93.
[PMID: 10782811]
[41]
Skacelova M, Hermanova Z, Horak P, Ahmed K, Langova K. Higher levels of matrix metalloproteinase-3 in patients with RA reflect disease activity and structural damage. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2017; 161(3): 296-302.
[http://dx.doi.org/10.5507/bp.2017.015] [PMID: 28461705]
[42]
Ahrens D, Koch AE, Pope RM, Stein-Picarella M, Niedbala MJ. Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. Arthritis Rheum 1996; 39(9): 1576-87.
[http://dx.doi.org/10.1002/art.1780390919] [PMID: 8814070]
[43]
Fraser A, Fearon U, Reece R, Emery P, Veale DJ. Matrix metalloproteinase 9, apoptosis, and vascular morphology in early arthritis. Arthritis Rheum 2001; 44(9): 2024-8.
[http://dx.doi.org/10.1002/1529-0131(200109)44:9<2024::AID-ART351>3.0.CO;2-K] [PMID: 11592363]
[44]
Tchetverikov I, Lard L, DeGroot J, Verzijl N, TeKoppele J, Breedveld F. Matrix metalloproteinases-3,-8,-9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. AnnRheumDis 2003; 62(11): 1094-9.
[45]
Hu W, Wei R, Wang L, Lu J, Liu H, Zhang W. Correlations of MMP-1, MMP-3, and MMP-12 with the degree of atherosclerosis, plaque stability and cardiovascular and cerebrovascular events. Exp Ther Med 2018; 15(2): 1994-8.
[PMID: 29434795]
[46]
Abdelnaseer M, Elfayomi N, Esmail EH, Kamal MM, Hamdy A, Samie RMA, et al. Relationship between matrix metalloproteinase-9 and common carotid artery intima media thickness. Neurological Sciences 2016; 37(1): 117-22.
[http://dx.doi.org/10.1007/s10072-015-2358-z]
[47]
Mattey DL, Nixon NB, Dawes PT. Association of circulating levels of MMP-8 with mortality from respiratory disease in patients with rheumatoid arthritis. Arthritis Res Ther 2012; 14(5): R204.
[http://dx.doi.org/10.1186/ar4042] [PMID: 23031278]
[48]
Rose BJ, Kooyman DL. A Tale of Two Joints: The role of matrix metalloproteases in cartilage biology. Dis Markers 2016; 2016: 4895050.
[http://dx.doi.org/10.1155/2016/4895050] [PMID: 27478294]
[49]
Di Caprio R, Lembo S, Di Costanzo L, Balato A, Monfrecola G. Anti-inflammatory properties of low and high doxycycline doses: an in vitro study. Mediators Inflamm 2015; 2015: 329418.
[http://dx.doi.org/10.1155/2015/329418] [PMID: 25977597]

Rights & Permissions Print Cite
Article Metrics
13
© 2024 Bentham Science Publishers | Privacy Policy